^
Association details:
Biomarker:PAK4 overexpression
Cancer:Melanoma
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

869P - PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

Published date:
09/05/2022
Excerpt:
Baseline patient samples were classified as responders (n = 9) or non-responders (n = 15) based on the response at 3 months post ICI-treatment….PAK4 was found to be elevated in tumor samples from non-responder patients by both unbiased proteomics analysis...Analysis of the 24 FFPE samples from metastatic melanoma patients treated with ICI therapy stratified into responders and non-responders lead to the identification of PAK4 as a potential marker for poor response to immunotherapy in melanoma patient samples.